MindWalk Holdings (TQB0) Stock Price & Analysis
TQB0 Stock Chart & Stats
- Day’s Range
- EUR 1.00 - EUR 1.00
- 52-Week Range
- EUR 0.84 - EUR 2.80
- Previous Close
- EUR 1.01
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 47.67M
- Enterprise Value
- EUR 57.43M
- Total Cash (Recent Filing)
- EUR 7.63M
- Total Debt (Recent Filing)
- EUR 3.49M
- Price to Earnings (P/E)
- ―
- Beta
- 1.64
- Next Earnings
- Dec 10, 2026 (Est.)
- EPS Estimate
- -0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Pharmaceutical Customer Base
Deep relationships with leading pharmaceutical companies and a track record spanning dozens of clinical molecules support credibility in a specialized market. This customer access can underpin recurring platform adoption and create durable opportunities for MindWalk’s discovery and data offerings.
Improving Revenue And Gross Margin
Five consecutive quarters of year-over-year revenue growth alongside materially higher gross margin indicate improving commercial traction and unit economics. If sustained, the stronger gross-profit contribution should provide more capacity to fund product development and move the business toward eventual operating leverage.
Platform Partnership Model
The shift from discrete project fees toward platform partnerships gives MindWalk potential to participate in milestone and royalty economics across client assets. A broader relationship model may deepen customer integration, increase recurring exposure, and expand revenue opportunities as programs progress.
Bears Say
Persistent Cash Burn
Sustained operating and free-cash-flow outflows show that current operations are not self-funding and that losses are translating into real cash consumption. Unless revenue accelerates or spending falls, continued burn will require financing and can constrain investment flexibility over the next several quarters.
Severe Unprofitability And Rising Costs
The larger loss and expanding operating investment raise the hurdle for ReefIQ and other platforms to achieve sufficient scale. Higher commercial and development spending can support growth, but without corresponding revenue conversion it prolongs the path to breakeven and increases funding pressure.
ReefIQ Revenue Uncertainty
ReefIQ’s strategic potential is not yet matched by predictable contracted revenue. Milestone-based starts, lengthy enterprise reviews, and uncertain closing dates make near-term sales conversion difficult to forecast, which complicates resource planning and delays visibility into the platform’s recurring revenue contribution.
MindWalk Holdings News
TQB0 FAQ
What was MindWalk Holdings’s price range in the past 12 months?
What is MindWalk Holdings’s market cap?
When is MindWalk Holdings’s upcoming earnings report date?
How were MindWalk Holdings’s earnings last quarter?
Is MindWalk Holdings overvalued?
Does MindWalk Holdings pay dividends?
What is MindWalk Holdings’s EPS estimate?
How many shares outstanding does MindWalk Holdings have?
What happened to MindWalk Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MindWalk Holdings?
What is the TipRanks Smart Score and how is it calculated?
MindWalk Holdings Stock Smart Score
Company Description
MindWalk Holdings
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jennifer Lynne Bath
- Employees
- 76
- Website
- www.mindwalkai.com
- Address
- Industrious 823 Congress Ave, Austin, TX, 78701, US
MindWalk Holdings (TQB0) Earnings & Revenues
TQB0 Company Deck
TQB0 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by 21% year-over-year revenue growth, five consecutive quarters of year-over-year growth, gross margin expansion to 59%, progress launching ReefIQ, a strong pharmaceutical customer base, clinical validation, platform partnership traction, and a USD 30 million non-dilutive financing commitment. The main negative factors were the increased $6.1 million loss, higher operating expenses, a lower cash balance, uncertain and potentially lumpy timing for ReefIQ revenue, and the absence of announced enterprise contracts or specific closing timelines.
View all DE:TQB0 earnings summariesTQB0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 3 | 13 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 1 | 0 | 11 |
